Open AccessEpidermal growth factor receptor mutation‐guided treatment for lung cancers: Where are we now?
Author(s) -
Su Zengliu
Publication year - 2011
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/j.1759-7714.2010.00035.x
Subject(s) - gefitinib , t790m , erlotinib , medicine , epidermal growth factor receptor , lung cancer , cancer research , tyrosine kinase , exon , mutation , egfr inhibitors , protein kinase domain , tyrosine kinase inhibitor , erlotinib hydrochloride , oncology , cancer , gene , receptor , biology , genetics , mutant
Epidermal growth factor receptor (EGFR) kinase domain mutations (from exon 18 to 21) alter the efficacy of the EGFR tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva). Lung cancer patients with drug‐sensitive EGFR mutations initially respond, but acquire resistance after approximately one year of tyrosine kinase inhibitor treatment. This review summarizes EGFR gene mutation profiles for East Asian non‐small‐cell lung cancer patients according to recent publications. Strategies for the treatment of acquired resistance mediated by EGFR T790M are also reviewed.